WO2008075462A1 - 胃酸分泌抑制作用を併せ持つヘリコバクター・ピロリ除菌剤 - Google Patents
胃酸分泌抑制作用を併せ持つヘリコバクター・ピロリ除菌剤 Download PDFInfo
- Publication number
- WO2008075462A1 WO2008075462A1 PCT/JP2007/001419 JP2007001419W WO2008075462A1 WO 2008075462 A1 WO2008075462 A1 WO 2008075462A1 JP 2007001419 W JP2007001419 W JP 2007001419W WO 2008075462 A1 WO2008075462 A1 WO 2008075462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gastric
- pylori
- helicobacter
- compound
- acid secretion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a Helicopacter pylori sterilizing agent having an excellent gastric acid secretion inhibiting action.
- Gastritis, gastric ulcer, and duodenal ulcer are diseases that develop due to complex intertwining of factors such as stress, genetic predisposition and lifestyle habits.
- H. pylori has attracted attention as one of the main causes. 1 9 8 3 years! 1! / 3 6 n and Marsha l I have succeeded in the isolation and cultivation of spiral-shaped bacteria from gastric biopsy specimens, and the relationship between gastritis, gastric ulcer, duodenal ulcer and gastric cancer and this bacteria
- An energetic study was conducted on.
- the infection rate of Helicobacter pylori was about 4% for healthy stomach, about 83% for chronic gastritis, and about 6 for gastric ulcer.
- Non-Patent Document 1 9%, about 9 2 Q / & for duodenal ulcer, and about 51% for non-ulcer dyspepsia syndrome (see Non-Patent Document 1).
- Helicobacter pylori infection is strongly related to the incidence of gastric cancer, and WHO's international cancer research institute in 1944 has a strong causal relationship with Helicobacter pylori. It is said.
- H. pylori Antibiotics such as amoxicillin and clarithromycin are used in combination with antibiotics (PPI) for a week or more, and in some cases, metronidazole is added to this. And, by the large dose of antibacterial agent, useful bacteria in the intestine are also sterilized, resulting in loose stool, diarrhea and abnormal taste, glossitis, stomatitis and liver dysfunction, side effects such as hemorrhagic enteritis, There is concern about the possibility of facilitating the emergence of metacillin-resistant bacteria (MRSA).
- MRSA metacillin-resistant bacteria
- Patent Document 1 JP-A-6 1-5 0 9 7 9
- Patent Document 2 Japanese Patent Laid-Open No. 3-1 7 3 8 1 7
- Patent Document 3 Japanese Patent Laid-Open No. 5-2 4 7 0 3 5
- Patent Document 4 Japanese Patent Application Laid-Open No. 5-9-1 8 1 2 7 7
- Patent Document 5 Japanese Patent Laid-Open No. 7-6 9 8 8 8 Patent Document 6: Japanese Patent Laid-Open No. 3_48680
- Patent Document 7 Japanese Patent Laid-Open No. 2-209809
- Patent Document 8 JP-A-58-39622
- Non-Patent Document 1 Martin J. Blaser ,: CI in. Infectious Disease, 15; 386-393, 199 2
- Non-patent literature 2 Graham DY et. A I.: Ann. Intern. Med., 116; 705-708, 1992
- Non-patent literature 3 Thomas G. Kuehler, et al., J. Med. Chem. 1998, 41, 1777-178
- the present invention is effective for the prevention and / or treatment of a related disease of Helicopacter pylori, and specifically acts on Helicobacter pylori and does not act on enterobacteria. , And is stable against acid and has a gastric acid secretion inhibitory activity ⁇
- the inventors found that the acid stable and helicopterpylori activity is strong at MIC of 0.1 g / m I or less and does not act on human resident bacteria.
- Kobacter _ ⁇ Shows specific antibacterial activity against Helicobacter pylori and is effective against antibiotic-resistant bacteria such as clarithromycin, which is widely used for the eradication of Helicobacter _H.
- a group of compounds having specific action and effects having gastric acid secretion inhibitory action has been found.
- the present inventors have further found that the compound exhibits a sterilizing effect in a model animal infected with Helicobacter pylori in a single agent. Based on these findings, the present inventors have completed the present invention.
- R represents a linear alkyl group having 4 to 8 carbon atoms.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a pyridine derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof, and more specifically represented by the general formula (I). And a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the present invention provides a pyridine derivative represented by the above general formula (I) or a pyridine derivative thereof for producing a preparation for the prevention or treatment of a disease associated with Helicobacter pylori and / or a disease associated with gastric acid secretion.
- a pyridine derivative represented by the above general formula (I) or a pyridine derivative thereof for producing a preparation for the prevention or treatment of a disease associated with Helicobacter pylori and / or a disease associated with gastric acid secretion.
- pharmaceutically acceptable salts are examples of pharmaceutically acceptable salts.
- the present invention is represented by the general formula (I) in a patient who is suffering from or is likely to suffer from a disease involving Helicobacter pylori and / or a disease involving gastric acid secretion.
- the present invention also relates to a compound represented by the above general formula (I I I).
- a pyridine derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof is represented by the general formula (I) or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition comprising the pyridine derivative according to (1) or (2) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the above diseases are gastritis, gastric ulcer, duodenal ulcer, non-ulcer dyspepsia syndrome, Gastric MA LT lymphoma, gastric hyperplasia polyp, Helicobacter _ ⁇ High gastrinemia caused by gastrinemia due to gastrointestinal cancer or vaginitis, Helicobacter _ ⁇ inflammatory bowel disease caused by Helicobacter pylori, or after endoscopic resection of early gastric cancer
- the pharmaceutical composition according to the above (4) which is a stomach cancer.
- composition according to any one of (3) to (5) which further comprises another gastric acid secretion inhibitor and / or an antibacterial agent as an active ingredient.
- Helicopactor ⁇ The pyridine derivative according to (1) or (2) above or a pharmaceutical product thereof for producing a preparation for the prevention or treatment of a disease associated with Helicobacter pylori and / or a disease associated with gastric acid secretion Use of acceptable salts.
- the above diseases are gastritis, gastric ulcer, duodenal ulcer, non-ulcer dyspepsia syndrome, gastric MA LT lymphoma, gastric hyperplasia polyp, Helicobacter _ ⁇ Gastrointestinal cancer or vaginitis caused by high gastrinemia due to Pylori _ ⁇ Use according to (7) above, which is an inflammatory bowel disease caused by H. pylori, or a gastric cancer after endoscopic resection of early gastric cancer.
- Helicobacter _ The preparation for the prevention or treatment of diseases associated with Helicobacter pylori and / or diseases associated with gastric acid secretion further comprises other gastric acid secretion inhibitors and / or antibacterial agents as active ingredients Use according to (7) or (8) above.
- the disease is gastritis, gastric ulcer, duodenal ulcer, non-ulcer dyspepsia syndrome, gastric MA LT lymphoma, gastric hyperplasia polyp, Helicobacter _ Helicobacter _ ⁇ Inflammatory bowel disease caused by pills, or gastric cancer after endoscopic resection of early gastric cancer
- a pharmaceutical composition comprising the pyridine derivative according to (1) or (2) or a pharmaceutically acceptable salt thereof.
- a pile helicopter pylori agent comprising the pyridine derivative according to (1) or (2) or a pharmaceutically acceptable salt thereof.
- a gastric acid secretion inhibitor comprising the pyridine derivative according to (1) or (2) or a pharmaceutically acceptable salt thereof.
- a preventive or therapeutic agent for a disease or condition involving Helicopacter pylori and / or gastric acid secretion comprising the pyridine derivative according to (1) or (2) or a pharmaceutically acceptable salt thereof.
- the disease or condition is gastritis, gastric ulcer, duodenal ulcer, non-ulcer dyspepsia syndrome, gastric MA LT lymphoma, gastric hyperplastic polyp, or endoscopic gastric cancer after early gastric cancer resection, The preventive or therapeutic agent according to 20).
- a prophylactic or therapeutic agent for a disease or condition involving Helicopacter pylori comprising the novel pyridine derivative according to (1) or (2) or a pharmaceutically acceptable salt thereof.
- the disease or condition is gastrointestinal cancer or vaginitis caused by Helicobacter pylori hypergastrinemia, or helicobacter _ ⁇ inflammatory bowel disease caused by Helicobacter pylori (2 1) Or the preventive or therapeutic agent according to (2 2)
- the pyridine derivative and the salt thereof of the present invention not only have an excellent pile helicobacter action, but also have an effect that is extremely stable to acids and is not decomposed in gastric acid.
- it has gastric acid secretion inhibitory action, single agent has specific sterilization action against Helicobacter pylori, and various diseases related to Helicobacter-pylori and excessive gastric acid secretion Diseases such as gastritis, gastric ulcer, duodenal ulcer, non-ulcer dyspepsia syndrome, gastric MALT lymphoma, gastric hyperplastic polyp, gastric cancer after endoscopic resection of early gastric cancer, Helicobacter pylori It is useful as a prophylactic and / or therapeutic agent for gastrointestinal cancer or vaginitis caused by, or for inflammatory bowel disease caused by Helicobacter pylori.
- the pyridine derivatives and salts thereof of the present invention are particularly characterized in that they can be used as a prophylactic and / or therapeutic agent effective for these diseases as a single agent.
- FIG. 1 is a graph showing the results of a stability test of a compound of the present invention and a compound of a comparative example in an acidic hydrochloric acid solution (pH 2).
- the vertical axis in Fig. 1 shows stability (survival rate) (%), and the horizontal axis shows elapsed time (minutes).
- FIG. 2 shows the antibacterial activity against Helicobacter pylori by the presence or absence of oxidation of the thioether group of the compound of the present invention and the compound of the comparative example and the difference in carbon number of the alkyl group in the 4-position alkoxy group of pyridine.
- 3 is a graph showing the results of testing (MIC).
- the vertical axis in Fig. 2 represents M I C ( ⁇ g / m L), and the horizontal axis represents the carbon number of the alkyl group.
- the black circle in Fig. 2 dark blue in the original figure
- the gray circle mark red in the original figure
- the compound of the present invention exhibits strong antibacterial activity against clarithromycin-resistant and amoxicillin-insensitive strains ( (See Table 4), (5) Various compounds of the present invention No antibacterial activity is observed against gram-negative bacteria and gram-positive bacteria (see Table 5). (6) The compounds of the present invention exhibit gastric acid secretion inhibitory effects (see Table 7). It has a remarkable effect.
- the compound of the present invention is equivalent to or more than the triple combination of omebrazole + amoxicillin + clarithromycin widely used in the world as a Helicobacter pylori eradication therapy.
- the compounds are single agents that are as effective or better than these triple therapies.
- these compounds exhibit specific antibacterial activity against Helicobacter _H. Pylori, also show antibacterial activity against insensitive or tolerant bacteria of amoxicillin and claris mouthmycin, and have gastric acid secretion inhibitory activity, acid It is extremely stable against gastric acid, is not decomposed even in stomach acid, and has an excellent clinical effect.
- methylthio moiety is in the form of a thioether rather than an oxidized sulfinyl group, and that the 4-position alkoxy group of the pyridine ring is a specific alkyl group. It is due.
- the pyridine derivative represented by the general formula (I) or a salt thereof according to the present invention is a novel compound not described in any literature.
- R in the general formula (I) of the present invention is a linear alkyl group having 4 to 8 carbon atoms, preferably 5 to 7 carbon atoms.
- the linear alkyl group in the present invention is preferably an n-alkyl group, but is _CH 2 _R ′ (wherein R ′ represents a linear alkyl group having 3 to 7 carbon atoms, preferably 4 to 6 carbon atoms). Examples thereof include an alkyl group that is not branched in the middle of the alkoxy group.
- Preferred alkyl groups include n_butyl group, n-pentyl group, n-hexyl group, n-heptyl group, n-octyl group, etc. More preferred alkyl groups include n-pentyl group, n —Hexyl group, n-heptyl group.
- preferred compounds in the present invention include
- the pyridine derivative represented by the general formula (I) or a salt thereof according to the present invention includes a mercapto derivative represented by the formula (II) as a raw material compound, and a pyridyl represented by the general formula (III). It can be produced by reacting with a derivative.
- X in the pyridyl derivative represented by the general formula (I I I) is not particularly limited as long as it is a leaving group, but a preferable leaving group is a halogen atom. Examples of halogen atoms include chlorine, bromine, and iodine.
- the compound represented by the general formula (III) is a novel compound, and is useful as an intermediate in the production of the general formula (I) of the present invention. The compounds represented are provided.
- This reaction is preferably carried out in the presence of a base.
- bases used in this reaction include alkali metal hydrides such as sodium hydride and potassium hydride, sodium alcoholates such as sodium methoxide and sodium ethoxide, potassium carbonate, and sodium carbonate. And alkali metal carbonates and organic amines such as triethylamine.
- the solvent used in the reaction include alcohols such as methanol and ethanol, and dimethyl sulfoxide.
- the amount of the base used in the above reaction is a little excessive than usual, but a large excess of base may be used. For example, about 2 to 10 equivalents, more preferably about 2 to 4 equivalents.
- the reaction temperature is usually from about 0 ° C. to around the boiling point of the solvent used, and more preferably about 20 ° C. to 80 ° C.
- the reaction time can be appropriately selected, but is usually about 0.2 to 24 hours, more preferably about 0.5 to 2 hours, for example.
- the target compound (I) produced by the above reaction can be isolated and purified by conventional means such as recrystallization and chromatography.
- the pyridine derivative represented by the general formula (I) of the present invention can be converted into a pharmacologically acceptable salt by a commonly used means.
- salt examples include hydrochloride, bromate, iodate, phosphate, nitrate, sulfate, acetate, and kenate.
- the raw material compound represented by the general formula (III) used when the pyridine derivative represented by the general formula (I) of the present invention is produced can be produced by the following reaction steps. .
- a chloro derivative (VI) is produced by reacting a nitro compound represented by the formula (IV) with concentrated hydrochloric acid, and an alcohol derivative ROH (V) in the presence of a base in the chloro derivative (VI). Can be reacted to obtain an alkoxy derivative represented by the formula (VII).
- the base used at this time include alkali metals such as lithium, sodium, and potassium, sodium hydride, alkali metal hydrides such as potassium hydride, t_butoxy potassium, propoxy sodium, and ethoxy sodium.
- Alcohols such as sodium methoxide, potassium carbonate, lithium carbonate, sodium carbonate, hydrogen carbonated lithium, carbonates or bicarbonates of alkali metals such as sodium hydrogen carbonate, sodium hydroxide, hydroxy hydroxide
- metal hydroxides are as follows.
- Solvents used in the reaction include lower alcohols represented by ROH, ethers such as tetrahydrofuran and dioxane, And ketones such as acetone and methyl ethyl ketone, acetonitrile, dimethylformamide, dimethyl sulfoxide, and the like.
- the reaction temperature is appropriately selected from ice cooling to the vicinity of the boiling point of the solvent.
- the reaction time is about 1 to 48 hours.
- the alkoxy derivative (VII) thus obtained is heated to about 80 to 120 ° C. in the presence of acetic anhydride alone or a mineral acid such as sulfuric acid or perchloric acid to give a general formula (VIII)
- the 2-acetoxymethylviridine derivative represented by The reaction time is usually about 0.1 to 10 hours.
- a 2-hydroxymethylpyridine derivative represented by I X) can be produced.
- the alkali at this time include sodium hydroxide, potassium hydroxide, potassium carbonate, and sodium carbonate.
- Examples of the solvent used include methanol, ethanol and water. The reaction time is about 0.1 to 2 hours.
- the 2_halomethylpyridine derivative represented by the general formula (I I I) can be produced by halogenating the compound (I X) with a halogenating agent such as chlorinating agent such as thionyl chloride.
- a halogenating agent such as chlorinating agent such as thionyl chloride.
- the solvent used include black mouth form, dichloromethane, and tetrachloroethane.
- the reaction temperature is usually about 20 ° C to 80 ° C, and the reaction time is about 0.1 to 2 hours.
- the compound of the present invention or a salt thereof is stable against acid, and can eliminate or bacterioculate Helicobacter pylori in the body of an animal belonging to a mammal (typically a human). That is, the compound of the present invention or a salt thereof is effective as a pile helicopter l.
- the compound of the present invention or a salt thereof can suppress gastric acid secretion in an animal belonging to a mammal (typically a human). That is, the compound of the present invention or a salt thereof is also effective as a gastric acid secretion inhibitor.
- the present invention also relates to the elimination or bacteriolysis of Helicobacter pylori in mammals. And / or a method of inhibiting gastric acid secretion, comprising administering an effective amount of a compound of the present invention or a salt thereof to a mammal in need of the method.
- the present invention also provides the use of the compound of the present invention or a salt thereof in the manufacture of a pile helicobacter_ ⁇ pylori and / or gastric acid secretion inhibitor.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention or a salt thereof as an active ingredient and having both an anti-helicopacter pylori action and a gastric acid secretion inhibitory action.
- the compound of the present invention is a single agent and is characterized by having a helicopter pylori action and an inhibitory action on gastric acid secretion. Accordingly, it is preferable that the pharmaceutical composition contains only the compound of the present invention or a salt thereof as an active ingredient.
- the pharmaceutical composition may further contain other gastric acid secretion inhibitor and / or antibacterial agent as an active ingredient.
- Other gastric acid secretion inhibitors include H 2 blockers, proton pump inhibitors and the like.
- H 2 blockers examples include cimetidine, famotidine, and ranitidine
- proton pump inhibitors examples include lansoprazole and omebrazo. 1, rabebrazole, pantobrazole, etc., but are not limited thereto.
- the drug containing the compound of the present invention or a salt thereof is used for preventing or treating a disease associated with Helicobacter pylori and / or gastric acid secretion (preferably Helicobacter _ pylori and gastric acid secretion). It is valid.
- a disease involving Helicobacter _ H. pylori refers to a disease caused or exacerbated by infection, survival or proliferation of Helicobacter pylori in vivo.
- Diseases involving gastric acid secretion refer to diseases caused or exacerbated by gastric acid secretion.
- Such diseases include gastritis, gastric ulcer, duodenal ulcer, non-ulcer dyspepsia syndrome, gastric MALT lymphoma, gastric hyperplasia polyp, Helicobacter pylori-induced gastrointestinal cancer or vaginitis Recopactor ⁇ Inflammatory bowel disease caused by H. pylori, gastric cancer after endoscopic resection of early gastric cancer, etc. Endoscopy of early gastric cancer Regarding gastric cancer after mirror resection, the carcinogenesis can be delayed or prevented by the compound of the present invention or a salt thereof.
- the drug containing the compound of the present invention or a salt thereof is also effective for preventing or treating a disease associated with Helicopacter pylori.
- diseases include gastrointestinal cancer or vaginitis caused by hypergastrinemia caused by Helicobacter pylori, or inflammatory bowel disease caused by Helicobacter pylori.
- the progression can be delayed or inhibited by the compound of the present invention or a salt thereof.
- the present invention also provides a method for preventing or treating a disease involving Helicobacter pylori and / or gastric acid secretion, wherein an effective amount of the compound of the present invention or a salt thereof is administered to a mammal in need of the method.
- a method comprising administering is provided.
- the present invention also provides use of the compound of the present invention or a salt thereof in the manufacture of a prophylactic or therapeutic agent for a disease involving Helicobacter pylori and / or gastric acid secretion.
- the present invention also provides a method for preventing or treating a disease involving Helicopacter pylori, comprising administering an effective amount of the compound of the present invention or a salt thereof to a mammal in need of the method. Provide a method.
- the present invention also provides use of the compound of the present invention or a salt thereof in the manufacture of a prophylactic or therapeutic agent for a disease associated with Helicobacter pylori.
- oral dosage forms for example, powders, Fine granules, granules, tablets, coated tablets and force pushells
- oral liquid preparations eg dry syrups, syrups, oral solutions and elixirs
- injections eg subcutaneous, intramuscular and intravenous injections
- medicaments may appropriately contain pharmaceutically acceptable excipients, carriers and the like in addition to the active ingredients.
- excipients include corn starch, lactose, sucrose, sodium chloride, mannitol, sorbitol, glucose, starch, Calcium carbonate, kaolin, microcrystalline cellulose, silicic acid, etc.
- binders are water, ethanol, gum arabic, tragacanth, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, hydroxypropyl cellulose, gelatin Hydroxypropyl starch, methylcellulose, ethyl cellulose, shellac, calcium phosphate, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, etc. are used, and disintegrating agents include gelatin powder, crystalline cellulose Dry starch, sodium alginate, pectin, agar powder, carboxymethyl cellulose, sodium bicarbonate, carbonated calcium, calcium citrate, sodium lauryl sulfate, monoglyceride stearate, lactose, etc.
- talc Refined talc, stearate, borax, polyethylene glycol, etc., and those that are allowed to add titanium oxide, iron oxide, etc. as coloring agents, white sugar, orange as flavoring agents
- coloring agents white sugar, orange as flavoring agents
- examples include leather, citrate, and tartaric acid.
- an oral solution, syrup, elixir and the like can be produced by a conventional method by adding a corrigent, buffer, stabilizer, flavor, etc. to the compound of the present invention.
- a corrigent such as those listed above
- the buffering agent may be sodium quenate
- the stabilizer may be tragacanth, gum arabic, gelatin or the like.
- a pH regulator, a buffer, a stabilizer, a tonicity agent, a local anesthetic, etc. are added to the compound of the present invention, and subcutaneous, intramuscular and intravenous are added by a conventional method.
- pH regulators and buffers in this case include sodium citrate, sodium acetate, and sodium phosphate.
- stabilizer include sodium pyrosulfite, EDTA, thioglycolic acid, and thiolactic acid.
- Local anesthetics include hydrochloric acid pro-power-in, salt Examples include acid lidocaine.
- the isotonic agent include sodium chloride and glucose.
- the amount of the compound of the present invention to be formulated in each of the above dosage unit forms is not constant depending on the patient to which this is to be applied, its symptom, or its dosage form, but generally per dosage unit form. It is desirable that the dosage is about 1-1200 mg for oral preparations and about 0.1-500 mg for injections.
- the daily dose of the drug having the above dosage form varies depending on the patient's symptoms, body weight, age, sex, etc., but cannot generally be determined, but is usually about 0.1 to 5000 mg per day for an adult. Preferably, it may be 1 to 12 O Omg, which is preferably administered once a day or divided into 2 to 4 times a day.
- Hydroxyacetic acid 55.0 g (5.0 eq.) was added to 2_9 g of 4_ethoxy-1,2,3-dimethylviridine_1-oxide, and reacted at 90 to 100 ° C. for 6 hours.
- the concentrated residue obtained after distilling off acetic anhydride was purified by silica gel ram to give 28.2 g of 2-acetoxymethyl-1-3-methyl-4-ethoxy-pyridine as an oil.
- 2-acetoxymethyl mono 3_methyl_ 4-ethoxy monopyridine 28.2 g was added dropwise to 25% aqueous sodium hydroxide solution, reacted at room temperature for 1 hour, diluted with toluene, then the toluene phase was washed with water, anhydrous magnesium sulfate After drying over, and concentrating to dryness, 2-hydroxymethyl-1-3-methyl-4-ethoxy-1-pyridine (10.7 g) was obtained as an oil.
- Acetic anhydride 44.0 g (4.0 eq.) was added to 4_propoxy-1,3-dimethyldimethylidine_1-oxide 20.3 g and reacted at 90 ° C. for 4 hours.
- the concentrated residue obtained after distilling off anhydrous acetic acid was purified by silica gel ram purification to obtain 27.8 g of 2-acetoxymethyl-1-3-methyl-4-propoxy-pyridine as an oil.
- 4_Pentyloxy_2-acetoxymethyl-1-methylpyridine 22.0 g (0. 088 mo I, 1.0 eq.) was added dropwise to 25% aqueous sodium hydroxide solution, reacted at room temperature for 1 hour, diluted with toluene, Next, the toluene phase was washed with water, dried over anhydrous magnesium sulfate, and concentrated to dryness to obtain 1_2 g of 4_pentyloxy_2-hydroxymethyl-3-methylpyridine (yield 60. 8%).
- 4_decyloxy_2-acetoxymethyl-1-methylpyridine 18.6 g (0. 058mo I, 1.0 eq.) was added dropwise to a 20% aqueous sodium hydroxide solution (23 g) at 11-22 ° C. After reaction at room temperature for 1 hour, water (93 mL) was added, followed by extraction with toluene (1 30 mL). Wash the extract with water, anhydrous sulfur After drying with magnesium acid and concentrating to dryness, 20.6 g of 4_decyloxy-2-hydroxymethyl-1-methylpyridine was obtained as a brown oil.
- 4-pentyloxy_2-hydroxymethyl-3-methylpyridine 11.0 g (0.054mo I, 1.0 eq.) Was dissolved in 620 ml L-form, 24.9 g (0. 281 mo I, 4 eq.) Was added dropwise at 22-30 ° C. Subsequently, the mixture was heated to reflux for 1 hour and then concentrated to obtain 4_pentyloxy-1-2_chloromethyl-1-3-methylpyridine as a brown oil.
- the yellowish brown oily residue was dissolved in 25 O mL of ethyl acetate, and the organic layer was washed with 1 O O mL of water. The organic layer was dried over anhydrous magnesium sulfate and concentrated to dryness. The obtained residue was purified by silica gel column chromatography and then concentrated to dryness to obtain 17.8 g of an orange oily substance. The orange oily substance was recrystallized with ethyl acetate (7 v o L) to obtain 8.7 g of colorless crystals (HPLC: 99.0 Area%, yield 38.7%).
- 2-acetoxymethyl mono 3_methyl _4-ethoxy monopyridine 10.7 g is dissolved in black mouth form, 28.2 g (4 eq.) Of thionyl chloride is added, and the mixture is heated to reflux for 1 hour and concentrated. Dissolve the residue in methanol and add it in advance to 2_mercaptobenzimidazole 8.4 g (1 eq.), 28% sodium methoxide solution 7 1 mL, methanol 150 mL Heated to reflux. Methanol was distilled off, and ice and ethyl acetate were added to the residue, followed by suspension washing. The produced crystals were collected by filtration, dissolved in methanol, and dried over anhydrous magnesium sulfate.
- 2-acetoxymethyl mono 3-methyl-4 propoxy monopyridine 11.0 g was dissolved in chloroform, added 30 g (4 eq.) Thionyl chloride, heated to reflux for 1 hour, and concentrated. It was dissolved in methanol, added in advance to 8.7 g (1 eq.) Of 2_mercaptobenzimidazole, 28 mL of sodium methoxide solution 73 mL, and methanol 30 OmL and heated to reflux for 1 hour. The methanol was distilled off, ice was added to the residue, extracted with ethyl acetate, and the ethyl acetate layer was dried over anhydrous magnesium sulfate.
- the orange oily residue was dissolved in 300 mL of ethyl acetate, and the organic layer was washed with 150 mL of water. After adding 45 g of silica gel to the organic layer and stirring, the silica gel was removed by filtration, and the filtrate was concentrated to dryness under reduced pressure to obtain 18.5 g of pale orange crystals. The pale orange crystals were recrystallized with ethyl acetate (to 10 V o) to obtain 9.7 g of pale orange crystals (HP LC: 99.6 A rea%, yield 47.1 / o). .
- the aqueous layer from which the dichloromethane layer had been removed was added with 1 1.2 1 g of 10% aqueous ammonium acetate solution, adjusted to pH 10.4 9 and extracted with 50 mL of dichloromethane.
- the organic layer was concentrated under reduced pressure at 40 ° C or lower, mixed with 1.35 g of acetone and 27.0 g of n-hexane, and the precipitated solid was collected by filtration to obtain a gray-green amorphous powder.
- Reference Example 8 ( ⁇ ) _ 2 _ [(4 _ n-heptyloxy _ 3 _methyl pyridi _2_yl) —methylsulfinyl] _ 1 H-benzimidazole 2-[(4-heptyloxy 3 _methylpyridine 1 2 _yl) monomethylthio] _ 1 H-benzimidazole Dissolve 1.00 g (2.7 mm o I, 1.0 eq.) In 7.6 mL of dichloromethane and cool to _20 ° C or less under nitrogen atmosphere.
- m-chloroperbenzoic acid (0.61 g, 5.8 mmo I, 2.1 eq.) In dichloromethane 6.
- OmL was added dropwise at -20 ° C or lower over 0.5 hours. The temperature was kept below _20 ° C and stirred for 40 minutes. After the liquid temperature reached 20 ° C., 6.0 g of 10% aqueous sodium hydroxide solution and 30 mL of water were added, and the aqueous layer was adjusted to pH 1 3.16. The aqueous layer from which the dichloromethane layer was removed was further washed with 12 mL of dichloromethane.
- OMZ in the table represents omeprazole, L A Z represents lansoprazole, and R A Z represents rabebrazole.
- Oxide of Example 1 is the compound shown in Reference Example 6
- Oxide of Example 2 is the compound shown in Reference Example 7
- Reference Example. 8 is a compound shown.
- the vertical axis in Fig. 1 indicates stability (residual rate) (%), and the horizontal axis indicates elapsed time (minutes).
- the black rhombus mark (original figure is amber) in Fig. 1 shows the case of the compound of Example 1
- the black square mark (original figure is red) shows the case of the compound of Example 2
- the white triangle mark (original figure is yellow) Indicates the case of the compound of Example 3
- the gray background (original is blue) indicates the case of the compound of Reference Example 6
- the black background (original is red) indicates that of the compound of Reference Example 7.
- the black circle mark (original figure is red) indicates the case of the compound of Reference Example 8, the gray vertical line mark (original figure is blue) indicates the case of omebrazole (OMZ), and the upper black mark (original figure is amber) Indicates the case of lansoprazole (LAZ), and the upper gray mark (blue in the original figure) indicates the case of rabebrazole (RAZ).
- the vertical axis in Fig. 2 represents MIC ( ⁇ g / m L), and the horizontal axis represents the carbon number of the alkyl group.
- the black circle in Fig. 2 (dark blue in the original figure) shows the case of SH, and the gray circle (red in the original figure) shows the case of SO.
- anti-HP activity is specifically enhanced in SH compounds with specific linear carbon numbers in the range of 2-9, especially in the range of 4-8. I understood it.
- the activity was maximum at linear carbon numbers of 5, 6, and 7, indicating 0.1 gZm l.
- the straight carbon number increases to 8 and 9, the helicobacter pylori action is attenuated.
- the MIC is 0.3 and 1.0 gZm L, respectively, and the carbon number is 1 Compared to the cases of 1/10 and 1/3, respectively.
- the anti-HP activity of the SO compound corresponding to Examples 1, 2, and 3 showing the largest anti-helicobacter pylori activity is Regardless of the prime number, they were all weak at 3.0 U g / m L.
- the present invention was the first to find that the helicopterpylori activity fluctuates greatly depending on the carbon number of the linear alkyl group of the 4-position substituent of the pyridine ring. It has been found that it becomes maximal at chain carbon numbers of 5, 6, and 7 and does not simply depend on the number of carbon atoms. And the maximum value is about 30 times that of 1 or 10 carbon atoms. In addition, we were able to confirm the surprising result that it was about 30 times stronger than the corresponding SO compound.
- AMPC amoxicillin
- CAM clarithromycin
- the compound of Comparative Example 1 is 2 _ [(4_isobutoxy_3-methylvinylidine_2_yl) methylthio] _1H-benzimidazole
- the compound of Comparative Example 2 is 2 _ [(4 _Isobutoxy pyridine _ 2 _methyl) methylthio] _ 1 H-benzimidazole.
- the antibacterial activity test of the compound of the present invention against Helicobacter pylori clarithromycin-resistant and amoxicillin-insensitive strains was carried out.
- the antibacterial activity test of the compound of the present invention was carried out using Claris mouthmycin resistant strain and amoxicillin insensitive strain of Helicobacter _H. Pylori isolated in clinical. Each strain was subjected to an in vitro test on Columbia agar medium. Each specimen was dissolved in 1% DMSO solution. 3 7 ° C, pH 7.0 to The minimum growth inhibitory concentration (MIC, U g / m I) was determined on the 4th day.
- MIC minimum growth inhibitory concentration
- CAM represents clarithromycin
- AMP C represents amoxicillin
- the compounds of Examples 1, 2, and 3 showed strong antibacterial activity against the clarithromycin resistant strain and the amoxicillin insensitive strain.
- Amoxicillin and Claris mouth mycin are widely used for the eradication therapy of Helicobacter pylori.
- the number of clarithromycin resistant strains is increasing, so that the present invention is also effective against resistant bacteria. It was found that its clinical usefulness is extremely high.
- Gram-negative bacteria include ⁇ ⁇ col i (AT CC 1 0536, AT CC 25 922), Klebsiel la pneumon ia (AT CC 1 003 1), Proteus vu I ga r is (AT CC 1 33 1 5), Pseudomonas aerug i nosa (AT CC 902 7) and Salmonel la typhi murium (AT CC 1 33 1 1), and Gram-positive bacteria include Staphylococcus aureus, MRSA (AT CC 3359 1), Staphylococcus epidermidis (AT CC 1 2228), Streptococcus p neumonia (AT CC 630 1), Mycobacter ium ranae (AT CC 110), and Enterococcus faecal is (VRE, AT CC 51 575).
- AMPC Amoxicillin CAM: Clarithromycin
- GEM Gentamicin
- AMPC amoxicillin
- CAM clarithromycin
- GEM gentamicin
- Helicopactor ⁇ Infects H. pylori experimentally with sand mice, The anti-ulcer action of the product and the eradication action of Helicopacter pylori were tested.
- Helicobacter pylori ATCC 43504
- the drug was administered twice a day for 2 weeks. Thereafter, the animals were fasted for 3 weeks, fasted for 18 hours, necropsied after laparotomy, and the degree of gastric ulcer and the number of Helicobacter pylori bacteria and the antibody titer of gastric mucosa were measured.
- the compound of Comparative Example 1 is 2 _ [(4-Isobutoxy-1-methylpyridine_2_yl) methylthio] _1H-benzimidazole
- the compound of Comparative Example 2 is 2 _ [(4 _Isobutoxy pyridine _ 2 _yl) methylthio] _ 1 H-benzimidazole.
- OMZ indicates omeprazole
- CAM indicates clarithromycin
- AM PC indicates amoxicillin.
- the compound of the present invention alone showed an anti-ulcer action and an antibacterial action against Helicobacter pylori in the same manner as the active control.
- the compound of Example 1 suppressed the occurrence of ulcers even at a low dose of 1 O mg / kg, and exhibited a strong sterilizing action against Helicobacter pylori. This strongly indicated that this drug is extremely useful as a disinfectant for Helicobacter pylori in clinical practice.
- the gastric acid secretion inhibitory action of the compound of the present invention was tested.
- a group of 5 male SD rats (about 200 g) was used, each drug was dissolved in 0.5% C M C, and 3 O mg / kg of each drug was administered into the duodenum. From the day before the test substance was administered until the administration, the animals were fasted and pylorus ligation was performed. Four hours later, under etheric intoxication, the stomach was removed and the gastric juice volume and total acidity were measured according to standard methods.
- Control drug cimetidine
- control drug in Table 7 is cimetidine.
- 0MZ omebrazole
- LAZ lansoprazole
- RAZ rabebrazole
- AMPC Amoxicillin
- CAM Clarithromycin
- OMZ represents omebrazole
- LAZ represents lansoprazole
- RAZ represents rabeprazole
- AM PC represents amoxicillin
- CAM represents clarithromycin.
- SO form sulfoxide compound
- SH form thioether compound
- the linear carbon number of R is 5, 6 , 7 has been shown to exhibit a specific Bacterial activity against a very strong pile.
- these three types of compounds also demonstrated the sterilization effect of Helicobacter pylori in a single agent even in an in vivo infection model using sand mice.
- the strength of the action was equivalent to or better than the combined use of omebrazole + amoxicillin + clarithromycin, which is widely used in the world as a sterilization therapy for Helicobacter _H. Pylori.
- the compound of the present invention exhibits specific antibacterial activity against Helicobacter pylori, and also exhibits antibacterial activity against insensitive or resistant bacteria of amoxicillin and claris mouthmycin, and has gastric acid secretion inhibitory activity. confirmed.
- Compound 1 (Compound prepared in Example 1) 5 0.0 mg Manni I 2 0.5 mg Hydroxypropyl Cell Mouth — 2.5 mg Crystalline Cellulose 1 0.0 mg Corn Starch 1 0.0 mg Cal Po carboxymethylcellulose ⁇ calcium 5. 0 mg talc 2. 0 mg magnesium stearate 0. in 2 mg above mix ratio in accordance with a conventional method, per tablet 1 0 O c formulation tablets were prepared in mg example 2 granules
- a syrup was prepared according to a conventional method at the above blending ratio.
- Compound 1 50 mg Famotidine 20mg Cyclodextrin 26mg
- the present invention is stable against acid, has an antibacterial action against Helicobacter pylori, exhibits a sufficient antibacterial action with a single agent, does not act on enteric bacteria, and is resistant to antibacterial agents
- the present invention provides a compound having antibacterial activity against bacteria and gastric acid secretion inhibitory activity, and a pharmaceutical composition using the same, and is useful in the pharmaceutical industry and has industrial applicability. Yes.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008550044A JP5097126B2 (ja) | 2006-12-18 | 2007-12-18 | 胃酸分泌抑制作用を併せ持つヘリコバクター・ピロリ除菌剤 |
AU2007335663A AU2007335663B2 (en) | 2006-12-18 | 2007-12-18 | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
CN2007800428046A CN101553480B (zh) | 2006-12-18 | 2007-12-18 | 兼具抑制胃酸分泌作用的幽门螺杆菌除菌剂 |
PL07849849T PL2103608T3 (pl) | 2006-12-18 | 2007-12-18 | Środek do eradykacji Helicobacter pylori mający działanie hamujące na sekrecję kwasu żołądkowego |
KR1020097010422A KR101283682B1 (ko) | 2006-12-18 | 2007-12-18 | 위산 분비 억제작용을 지닌 헬리코박터 피로리 제균제 |
BRPI0720539-2A BRPI0720539A2 (pt) | 2006-12-18 | 2007-12-18 | Derivado de piridina, composição farmacêutica, uso do mesmo, métodos para prevenir ou tratar uma doença, e para produzir um derivado de piridina |
CA2671949A CA2671949C (en) | 2006-12-18 | 2007-12-18 | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
EP07849849A EP2103608B1 (en) | 2006-12-18 | 2007-12-18 | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
US12/519,453 US8778975B2 (en) | 2006-12-18 | 2007-12-18 | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
DK07849849.0T DK2103608T3 (da) | 2006-12-18 | 2007-12-18 | Helicobacter pylori eradikerende middel med inhiberende virkning på mavesyresekretion |
SI200731064T SI2103608T1 (sl) | 2006-12-18 | 2007-12-18 | Sredstvo za eradikacijo Helicobacterja pylori z inhibitorno aktivnostjo za izločanje želoldčne kisline |
ES07849849T ES2390611T3 (es) | 2006-12-18 | 2007-12-18 | Agente de erradicación de Helicobacter pylori que tiene actividad inhibidora sobre la secreción de ácido gástrico |
MX2009006638A MX2009006638A (es) | 2006-12-18 | 2007-12-18 | Agente para erradicar helicobacter pylori que tiene actividad inhibidora sobre la secrecion de acido gastrico. |
HK09110997.3A HK1131149A1 (en) | 2006-12-18 | 2009-11-25 | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-340323 | 2006-12-18 | ||
JP2006340323 | 2006-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008075462A1 true WO2008075462A1 (ja) | 2008-06-26 |
Family
ID=39536102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/001419 WO2008075462A1 (ja) | 2006-12-18 | 2007-12-18 | 胃酸分泌抑制作用を併せ持つヘリコバクター・ピロリ除菌剤 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8778975B2 (ja) |
EP (1) | EP2103608B1 (ja) |
JP (1) | JP5097126B2 (ja) |
KR (1) | KR101283682B1 (ja) |
CN (1) | CN101553480B (ja) |
AU (1) | AU2007335663B2 (ja) |
BR (1) | BRPI0720539A2 (ja) |
CA (1) | CA2671949C (ja) |
DK (1) | DK2103608T3 (ja) |
ES (1) | ES2390611T3 (ja) |
HK (1) | HK1131149A1 (ja) |
MX (1) | MX2009006638A (ja) |
PL (1) | PL2103608T3 (ja) |
PT (1) | PT2103608E (ja) |
RU (1) | RU2451682C2 (ja) |
SI (1) | SI2103608T1 (ja) |
WO (1) | WO2008075462A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010116740A1 (ja) | 2009-04-09 | 2010-10-14 | アリジェン製薬株式会社 | ピリジンチオ誘導体及びそれを含有する抗ヘリコバクター・ピロリ作用を有する医薬組成物 |
WO2021181366A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc | Materials and methods for binding siglec-3/cd33 |
WO2021240388A1 (en) | 2020-05-27 | 2021-12-02 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
WO2022201053A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
WO2022201052A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Antibody targeting cd22 and cd79b |
WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110003176B (zh) * | 2019-05-28 | 2021-12-21 | 沈阳药科大学 | 含有酰胺的苯并咪唑类化合物及其应用 |
CN110003177B (zh) * | 2019-05-28 | 2021-11-19 | 沈阳药科大学 | 含有脲基的苯并咪唑类化合物及应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5839622A (ja) | 1981-08-13 | 1983-03-08 | アクチエボラゲツト・ヘツスレ | 胃酸分泌抑制剤 |
JPS59181277A (ja) | 1983-02-11 | 1984-10-15 | アクチエボラゲツト・ヘツスレ | 新規な薬理学的に活性な化合物 |
JPS6150979A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
JPH02209809A (ja) | 1989-02-09 | 1990-08-21 | Fujisawa Pharmaceut Co Ltd | 抗菌剤 |
JPH0348680A (ja) | 1989-07-18 | 1991-03-01 | Yoshitomi Pharmaceut Ind Ltd | 抗菌剤 |
JPH03173817A (ja) | 1989-02-10 | 1991-07-29 | Takeda Chem Ind Ltd | 抗菌剤 |
JPH05247035A (ja) | 1986-11-13 | 1993-09-24 | Eisai Co Ltd | ピリジン誘導体及びそれを含有する潰瘍治療剤 |
JPH0769888A (ja) | 1992-08-21 | 1995-03-14 | Eisai Co Ltd | 抗菌剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2149872C1 (ru) * | 1994-07-20 | 2000-05-27 | Бык Гульден Ломберг Хемише Фабрик Гмбх | Пиридилтиосоединения для борьбы с бактериями helicobacter |
ES2171116B1 (es) | 2000-04-14 | 2003-08-01 | Esteve Quimica Sa | Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol. |
CA2480890A1 (en) * | 2002-03-29 | 2003-10-09 | Zeria Pharmaceutical Co., Ltd. | 1-n-aminobenzimidazole derivatives |
-
2007
- 2007-12-18 AU AU2007335663A patent/AU2007335663B2/en not_active Ceased
- 2007-12-18 RU RU2009127750/04A patent/RU2451682C2/ru not_active IP Right Cessation
- 2007-12-18 WO PCT/JP2007/001419 patent/WO2008075462A1/ja active Application Filing
- 2007-12-18 ES ES07849849T patent/ES2390611T3/es active Active
- 2007-12-18 JP JP2008550044A patent/JP5097126B2/ja not_active Expired - Fee Related
- 2007-12-18 BR BRPI0720539-2A patent/BRPI0720539A2/pt not_active IP Right Cessation
- 2007-12-18 DK DK07849849.0T patent/DK2103608T3/da active
- 2007-12-18 SI SI200731064T patent/SI2103608T1/sl unknown
- 2007-12-18 PL PL07849849T patent/PL2103608T3/pl unknown
- 2007-12-18 EP EP07849849A patent/EP2103608B1/en not_active Not-in-force
- 2007-12-18 PT PT07849849T patent/PT2103608E/pt unknown
- 2007-12-18 CA CA2671949A patent/CA2671949C/en not_active Expired - Fee Related
- 2007-12-18 KR KR1020097010422A patent/KR101283682B1/ko not_active IP Right Cessation
- 2007-12-18 MX MX2009006638A patent/MX2009006638A/es active IP Right Grant
- 2007-12-18 US US12/519,453 patent/US8778975B2/en not_active Expired - Fee Related
- 2007-12-18 CN CN2007800428046A patent/CN101553480B/zh not_active Expired - Fee Related
-
2009
- 2009-11-25 HK HK09110997.3A patent/HK1131149A1/xx not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5839622A (ja) | 1981-08-13 | 1983-03-08 | アクチエボラゲツト・ヘツスレ | 胃酸分泌抑制剤 |
JPS59181277A (ja) | 1983-02-11 | 1984-10-15 | アクチエボラゲツト・ヘツスレ | 新規な薬理学的に活性な化合物 |
JPS6150979A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
JPH05247035A (ja) | 1986-11-13 | 1993-09-24 | Eisai Co Ltd | ピリジン誘導体及びそれを含有する潰瘍治療剤 |
JPH02209809A (ja) | 1989-02-09 | 1990-08-21 | Fujisawa Pharmaceut Co Ltd | 抗菌剤 |
JPH03173817A (ja) | 1989-02-10 | 1991-07-29 | Takeda Chem Ind Ltd | 抗菌剤 |
JPH0348680A (ja) | 1989-07-18 | 1991-03-01 | Yoshitomi Pharmaceut Ind Ltd | 抗菌剤 |
JPH0769888A (ja) | 1992-08-21 | 1995-03-14 | Eisai Co Ltd | 抗菌剤 |
Non-Patent Citations (7)
Title |
---|
GRAHAM D.Y. ET AL., ANN. INTERN. MED., vol. 116, 1992, pages 705 - 708 |
HIRAYAMA ET AL., J. GASTROENTEROL., vol. 31, no. 9, 1996, pages 24 - 8 |
KUHLER T.C. ET AL.: "Structure-activity relationship of 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy", J. MED. CHEM., vol. 41, no. 11, 1998, pages 1777 - 1788, XP002995740 * |
MARTIN J. BLASER, CLIN. INFECTIOUS DISEASE, vol. 15, 1992, pages 386 - 393 |
See also references of EP2103608A4 |
THOMAS C. KUEHLER ET AL., J. MED. CHEM., vol. 41, 1998, pages 1777 - 1788 |
THOMAS C. KUEHLER, J. MED. CHEM., vol. 41, 1998, pages 1777 - 1788 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5543432B2 (ja) * | 2009-04-09 | 2014-07-09 | リンク・ジェノミクス株式会社 | ピリジンチオ誘導体及びそれを含有する抗ヘリコバクター・ピロリ作用を有する医薬組成物 |
CN102378761A (zh) * | 2009-04-09 | 2012-03-14 | 阿利健制药有限公司 | 吡啶硫基衍生物以及含有该衍生物的具有抗幽门螺杆菌作用的医药组合物 |
EP2420500A4 (en) * | 2009-04-09 | 2012-09-05 | Arigen Pharmaceuticals Inc | PYRIDINTHIODERIVATE AND PHARMACEUTICAL COMPOSITION THEREOF AND WITH ANTI-HELIDOBACTER PYLORI EFFECT |
RU2484089C1 (ru) * | 2009-04-09 | 2013-06-10 | Ариджен Фармасьютикалз, Инк. | Тиопроизводное пиридина и фармацевтическая композиция, которая его содержит и имеет способность действовать против helicobacter pylori |
KR101353572B1 (ko) * | 2009-04-09 | 2014-01-22 | 링크 제노믹스 가부시키가이샤 | 피리딘티오 유도체 및 이를 함유하는 항-헬리코박터피로리 작용을 가지는 의약 조성물 |
EP2420500A1 (en) * | 2009-04-09 | 2012-02-22 | aRigen Pharmaceuticals, Inc. | Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action |
WO2010116740A1 (ja) | 2009-04-09 | 2010-10-14 | アリジェン製薬株式会社 | ピリジンチオ誘導体及びそれを含有する抗ヘリコバクター・ピロリ作用を有する医薬組成物 |
EP4233893A2 (en) | 2020-03-13 | 2023-08-30 | Janssen Biotech, Inc. | Materials and methods for binding siglec-3/cd33 |
WO2021181366A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc | Materials and methods for binding siglec-3/cd33 |
EP4233894A2 (en) | 2020-03-13 | 2023-08-30 | Janssen Biotech, Inc. | Materials and methods for binding siglec-3/cd33 |
EP4233895A2 (en) | 2020-03-13 | 2023-08-30 | Janssen Biotech, Inc. | Materials and methods for binding siglec-3/cd33 |
WO2021240388A1 (en) | 2020-05-27 | 2021-12-02 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
WO2022201052A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Antibody targeting cd22 and cd79b |
WO2022201053A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2671949C (en) | 2011-11-01 |
RU2451682C2 (ru) | 2012-05-27 |
JP5097126B2 (ja) | 2012-12-12 |
KR101283682B1 (ko) | 2013-07-08 |
CA2671949A1 (en) | 2008-06-26 |
EP2103608A4 (en) | 2010-12-22 |
EP2103608A1 (en) | 2009-09-23 |
KR20090101890A (ko) | 2009-09-29 |
EP2103608B1 (en) | 2012-08-29 |
CN101553480B (zh) | 2013-06-05 |
SI2103608T1 (sl) | 2012-12-31 |
ES2390611T3 (es) | 2012-11-14 |
BRPI0720539A2 (pt) | 2014-01-07 |
PL2103608T3 (pl) | 2013-02-28 |
US8778975B2 (en) | 2014-07-15 |
MX2009006638A (es) | 2009-07-02 |
DK2103608T3 (da) | 2012-09-17 |
RU2009127750A (ru) | 2011-01-27 |
JPWO2008075462A1 (ja) | 2010-04-08 |
US20100173944A1 (en) | 2010-07-08 |
CN101553480A (zh) | 2009-10-07 |
PT2103608E (pt) | 2012-09-24 |
AU2007335663A1 (en) | 2008-06-26 |
HK1131149A1 (en) | 2010-01-15 |
AU2007335663B2 (en) | 2011-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI90544B (fi) | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi | |
WO2008075462A1 (ja) | 胃酸分泌抑制作用を併せ持つヘリコバクター・ピロリ除菌剤 | |
RU2237666C2 (ru) | Калиевая соль (s)-омепразола, способ ее получения и фармацевтический препарат на ее основе | |
JP2650869B2 (ja) | 新規の5−ピロリル−6−ハロゲノ−2−ピリジルメチルスルフィニルベンゾイミダゾール誘導体およびその製造方法 | |
JP5053992B2 (ja) | 抗ヘリコバクター・ピロリ作用を有する新規ピリジン誘導体 | |
KR101353572B1 (ko) | 피리딘티오 유도체 및 이를 함유하는 항-헬리코박터피로리 작용을 가지는 의약 조성물 | |
WO1997040039A1 (fr) | Composes pyridiniques et utilisations medicales de ceux-ci | |
JPH1036367A (ja) | ピリジン化合物 | |
JPS63101381A (ja) | テトラゾ−ル基を有するピリジン誘導体およびそれを含む医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780042804.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07849849 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097010422 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2671949 Country of ref document: CA Ref document number: 2007335663 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008550044 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/006638 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007849849 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007335663 Country of ref document: AU Date of ref document: 20071218 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4488/DELNP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009127750 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12519453 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0720539 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090617 |